Seq&Treat – bringing next-generation TB care to underserved communities – is a project designed to generate evidence and boost in-country capacity to support the global adoption of commercial, targeted next-generation sequencing (NGS) for affordable, scalable and rapid TB drug-susceptibility testing (DST).
Why are we working on it?
Drug-resistant (DR-)TB is a public health crisis – in 2018, it was estimated that 500,000 people developed TB that was resistant to rifampicin, the most effective first-line drug, and 78% of those people had multidrug-resistant TB. Yet, only 187,000 DR-TB cases were detected and reported.
The spread of DR-TB is exacerbated by the lack of rapid, accurate diagnostic tests for comprehensive DST. Culture-based DST is the current standard of care, but it is slow and comes with significant biosafety hazards and minimal potential for cost reductions. Targeted NGS has the potential to revolutionize the DST landscape as it can provide faster, safer and more comprehensive results that can inform clinical decision-making for existing, repurposed and new DR-TB treatment regimens.
What does it involve?
NGS refers to sequencing technologies that can rapidly process millions of DNA sequences in parallel, to decode the genome of a person or bacterium and find genetic mutations that are associated with drug resistance – which means that a comprehensive drug resistance profile can be effectively identified for accurate diagnosis and management of DR-TB. It is a technique that is already well-established to inform personalized treatment decisions in oncology.
Seq&Treat aims to generate clinical evidence to support WHO global guidance for the use of targeted NGS for DR-TB diagnosis so that patients can be linked to the most appropriate care as fast as possible. In addition, it will establish a WHO global clinical knowledgebase, evaluate proof-of-principle delivery models for integrating targeted NGS into existing diagnostic work streams, and facilitate inclusion of recommended NGS solutions into global procurement mechanisms and adoption by low- and middle-income countries.
What do we expect to achieve?
Bringing the power of sequencing closer to communities with a high burden of DR-TB will enable rapid diagnosis and comprehensive treatment guidance in the short term, as well as catalyze an eventual decrease in the transmission of DR-TB, and reductions in DR-TB incidence and prevalence.
What is the timescale?
Seq&Treat will run for 3 years, from 2019 to 2021.
Partners and funding
Seq&Treat is a FIND project, funded by Unitaid, which builds on earlier sequencing work that has been supported by the Bill & Melinda Gates Foundation, the Australian government, and UK aid from the British people.
For more information please firstname.lastname@example.org.